Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 514

1.

Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.

Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT.

J Clin Oncol. 2005 Aug 20;23(24):5635-43.

2.

TP53 mutation and microsatellite instability status for the prediction of survival in adjuvant-treated colon cancer patients.

Watanabe T, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Ishihara S, Nagawa H.

J Clin Oncol. 2005 Dec 10;23(35):9031-2; author reply 9032-3. No abstract available.

3.

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.

Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.

Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67. doi: 10.1007/s00280-009-1206-3. Epub 2009 Dec 24.

PMID:
20033812
4.

Microsatellite instability and colorectal cancer prognosis.

Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, Ponti G, Santini A, Losi L, Di Gregorio C, Oliani C, Ponz de Leon M, Lanza G.

Clin Cancer Res. 2005 Dec 1;11(23):8332-40. Erratum in: Clin Cancer Res. 2006 Jun 15;12(12):3868-9.

5.

Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.

Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Verlind E, Hermans J, Poppema S, Buys CH, Plukker JT.

Dis Colon Rectum. 2001 Mar;44(3):358-63.

PMID:
11289281
6.

Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.

Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F.

Ann Oncol. 2010 Apr;21(4):772-80. doi: 10.1093/annonc/mdp383. Epub 2009 Oct 15.

7.

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M.

J Clin Oncol. 2009 Apr 10;27(11):1814-21. doi: 10.1200/JCO.2008.18.2071. Epub 2009 Mar 9.

8.
9.

p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.

Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, Iacopetta B.

Oncology. 2000;58(1):52-9.

PMID:
10644941
10.

Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.

Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, Plukker JT.

Am J Gastroenterol. 2000 Oct;95(10):2953-7.

PMID:
11051374
11.

Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.

Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ; National Cancer Institute.

J Clin Oncol. 2007 Mar 1;25(7):767-72. Epub 2007 Jan 16.

12.

Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.

van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ.

J Clin Oncol. 2006 Nov 1;24(31):4998-5004.

13.

Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.

Lamberti C, Lundin S, Bogdanow M, Pagenstecher C, Friedrichs N, Büttner R, Sauerbruch T.

Int J Colorectal Dis. 2007 Feb;22(2):145-52. Epub 2006 May 25.

PMID:
16724208
14.

Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.

Kumar S, Chang EY, Frankhouse J, Dorsey PB, Lee RG, Johnson N.

Arch Surg. 2009 Sep;144(9):835-40. doi: 10.1001/archsurg.2009.162.

PMID:
19797108
15.

Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers.

Westra JL, Plukker JT, Buys CH, Hofstra RM.

Clin Colorectal Cancer. 2004 Nov;4(4):252-9. Review.

PMID:
15555207
16.

Chemosensitivity and survival in gastric cancer patients with microsatellite instability.

Oki E, Kakeji Y, Zhao Y, Yoshida R, Ando K, Masuda T, Ohgaki K, Morita M, Maehara Y.

Ann Surg Oncol. 2009 Sep;16(9):2510-5. doi: 10.1245/s10434-009-0580-8. Epub 2009 Jun 30.

PMID:
19565284
17.

Low microsatellite instability is associated with poor prognosis in stage C colon cancer.

Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, Dent OF, Dhillon VS, Trent RJ, Chapuis PH, Bokey EL.

J Clin Oncol. 2005 Apr 1;23(10):2318-24.

18.

Prognostic and predictive relevance of microsatellite instability in colorectal cancer.

Storojeva I, Boulay JL, Heinimann K, Ballabeni P, Terracciano L, Laffer U, Mild G, Herrmann R, Rochlitz C.

Oncol Rep. 2005 Jul;14(1):241-9.

PMID:
15944796
19.

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, van den Brule AJ.

Ann Oncol. 2010 Dec;21(12):2396-402. doi: 10.1093/annonc/mdq258. Epub 2010 May 25.

Items per page

Supplemental Content

Write to the Help Desk